A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome

References

• Gataullina S, Dulac O. From genotype to phenotype in Dravet disease. Seizure. 2017 Jan;44:58–64.
   PubMed Web of Science ®Google Scholar
• Villas N, Meskis MA, Goodliffe S. Dravet syndrome: characteristics, comorbidities, and caregiver concerns. Epilepsy Behav. 2017 Sep;74:81–86.
   PubMed Web of Science ®Google Scholar
• Cooper MS, McIntosh A, Crompton DE, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016 Dec;128:43–47.
   PubMed Web of Science ®Google Scholar
• Shmuely S, Sisodiya SM, Gunning WB, et al. Mortality in Dravet syndrome: a review. Epilepsy Behav. 2016 Nov;64:69–74.
   PubMed Web of Science ®Google Scholar
• Bayat A, Hjalgrim H, Moller RS. The incidence of SCN1A -related Dravet syndrome in Denmark is 1:22,000: a population-based study from 2004 to 2009. Epilepsia. 2015 Apr;56:e36–9.
   PubMed Web of Science ®Google Scholar
• Brunklaus A, Ellis R, Reavey E, et al. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain. 2012 Aug;135:2329–2336.
   PubMed Web of Science ®Google Scholar
• Symonds JD, Zuberi SM, Stewart K, et al. Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain. 2019 Aug 1;142:2303–2318.
   PubMed Web of Science ®Google Scholar
• Steel D, Symonds JD, Zuberi SM, et al. Dravet syndrome and its mimics: beyond SCN1A. Epilepsia. 2017 Nov;58:1807–1816.
   PubMed Web of Science ®Google Scholar
• Mantegazza M, Broccoli V. SCN1A/NaV 1.1 channelopathies: mechanisms in expression systems, animal models, and human iPSC models. Epilepsia. 2019 Dec;60 Suppl 3:S25–S38.
   PubMed Web of Science ®Google Scholar
• Catterall WA. Dravet Syndrome: a Sodium Channel Interneuronopathy. Curr Opin Physiol. 2018 Apr;2:42–50.
   PubMed Web of Science ®Google Scholar
• Tran CH, Vaiana M, Nakuci J, et al. Interneuron desynchronization precedes seizures in a mouse model of dravet syndrome. J Neurosci. 2020 Mar 25;40:2764–2775.
   PubMed Web of Science ®Google Scholar
• Favero M, Sotuyo NP, Lopez E, et al. A transient developmental window of fast-spiking interneuron dysfunction in a mouse model of dravet syndrome. J Neurosci. 2018 Sep 5;38:7912–7927.
   PubMed Web of Science ®Google Scholar
• Aras LM, Isla J, Mingorance-Le Meur A. The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome. Epilepsy Behav. 2015 Mar;44:104–109.
   PubMed Web of Science ®Google Scholar
• Heger K, Lund C, Larsen Burns M, et al. A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway. Epilepsia Open. 2020 Sep;5:432–441.
   PubMedGoogle Scholar
• Cross JH, Caraballo RH, Nabbout R, et al. Dravet syndrome: treatment options and management of prolonged seizures. Epilepsia. 2019 Dec;60 Suppl 3:S39–S48.
   PubMed Web of Science ®Google Scholar
• Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of dravet syndrome: recommendations From a North American consensus panel. Pediatr Neurol. 2017 Mar;68:18–34 e3.
   PubMed Web of Science ®Google Scholar
• Schubert-Bast S, Wolff M, Wiemer-Kruel A, et al. Seizure management and prescription patterns of anticonvulsants in Dravet syndrome: a multicenter cohort study from Germany and review of literature. Epilepsy Behav. 2019 Sep;98:88–95.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Schubert-Bast S. Therapeutic advances in Dravet syndrome: a targeted literature review. Expert Rev Neurother. 2020 Oct;20:1065–1079.
   PubMed Web of Science ®Google Scholar
• de Lange IM, Gunning B, Sonsma ACM, et al. Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes. Epilepsia. 2018 Jun;59:1154–1165.
   PubMed Web of Science ®Google Scholar
• Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000 Nov 11;356:1638–1642.
   PubMed Web of Science ®Google Scholar
• Chiron C. Stiripentol for the treatment of seizures associated with Dravet syndrome. Expert Rev Neurother. 2019 Apr;19:301–310.
   PubMed Web of Science ®Google Scholar
• Wirrell EC, Nabbout R. Recent advances in the drug treatment of dravet syndrome. CNS Drugs. 2019 Sep;33:867–881.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017 May 25;376:2011–2020.
   PubMed Web of Science ®Google Scholar
• Miller I, Scheffer IE, Gunning B, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial. JAMA Neurol. 2020 May 1;77:613–621.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia. 2019 Feb;60:294–302.
   PubMed Web of Science ®Google Scholar
• Raucci U, Pietrafusa N, Paolino MC, et al. Cannabidiol treatment for refractory epilepsies in pediatrics. Front Pharmacol. 2020;11:586110.
   PubMed Web of Science ®Google Scholar
• Munro JF, Seaton DA, Duncan LJ. Treatment of refractory obesity with fenfluramine. Br Med J. 1966 Sep 10;2:624–625.
   PubMed Web of Science ®Google Scholar
• Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996 Aug 29;335:609–616.
   PubMed Web of Science ®Google Scholar
• Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997 Aug 28;337:581–588.
   PubMed Web of Science ®Google Scholar
• Baraban SC, Dinday MT, Hortopan GA. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun. 2013;4:2410.
   PubMed Web of Science ®Google Scholar
• Griffin A, Hamling KR, Knupp K, et al. Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain. 2017 Mar 1;140:669–683.
   PubMed Web of Science ®Google Scholar
• Sourbron J, Schneider H, Kecskes A, et al. Serotonergic modulation as effective treatment for dravet syndrome in a zebrafish mutant model. ACS Chem Neurosci. 2016 May 18;7:588–598.
   PubMed Web of Science ®Google Scholar
• Tolete P, Knupp K, Karlovich M, et al. Lorcaserin therapy for severe epilepsy of childhood onset: a case series. Neurology. 2018 Oct 30;91:837–839.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia. 2018 Oct;59(10):1811–1841.
   PubMed Web of Science ®Google Scholar
• Campbell C, Barohn RJ, Bertini E, et al. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. J Comp Eff Res. 2020 Oct;9:973–984.
   PubMed Web of Science ®Google Scholar
• Han Z, Chen C, Christiansen A, et al. Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. Sci Transl Med. 2020 Aug 26;12:eaaz6100.
   Web of Science ®Google Scholar
• Colasante G, Lignani G, Brusco S, et al. dCas9-based scn1a gene activation restores inhibitory interneuron excitability and attenuates seizures in dravet syndrome mice. Mol Ther. 2020 Jan 8;28:235–253.
   PubMed Web of Science ®Google Scholar
• Bagdy G, Kecskemeti V, Riba P, et al. Serotonin and epilepsy. J Neurochem. 2007 Feb;100:857–873.
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH. Serotonin releasing agents. Neurochemical, therapeutic and adverse effects. Pharmacol Biochem Behav. 2002 Apr;71:825–836.
   PubMed Web of Science ®Google Scholar
• Curzon G, Gibson EL, Oluyomi AO. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci. 1997 Jan;18:21–25.
   PubMed Web of Science ®Google Scholar
• Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol. 2000;57:75–81.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kecskes A, Copmans D, et al. Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine. PLoS One. 2015;10:e0125898.
   PubMed Web of Science ®Google Scholar
• Dinday MT, Baraban SC. Large-scale phenotype-based antiepileptic drug screening in a zebrafish model of dravet syndrome. eNeuro. 2015 Jul-Aug;2. DOI:https://doi.org/10.1523/ENEURO.0068-15.2015.
   Google Scholar
• Sourbron J, Smolders I, de Witte P, et al. Pharmacological analysis of the anti-epileptic mechanisms of fenfluramine in scn1a mutant zebrafish. Front Pharmacol. 2017;8:191.
   PubMed Web of Science ®Google Scholar
• Silenieks LB, Carroll NK, Van Niekerk A, et al. Evaluation of selective 5-HT 2C agonists in acute seizure models. ACS Chem Neurosci. 2019 Jul 17;10:3284–3295.
   PubMed Web of Science ®Google Scholar
• Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012 Jul;53:1131–1139.
   PubMed Web of Science ®Google Scholar
• Schoonjans A, Paelinck BP, Marchau F, et al. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients. Eur J Neurol. 2017 Feb;24:309–314.
   PubMed Web of Science ®Google Scholar
• Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019 Dec 21;394:2243–2254.
   PubMed Web of Science ®Google Scholar
• Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020 Mar 1;77:300–308.
   PubMed Web of Science ®Google Scholar
• Hatini PG, Commons KG. Serotonin abnormalities in Dravet syndrome mice before and after the age of seizure onset. Brain Res. 2019 Dec 1;1724:146399.
   PubMed Web of Science ®Google Scholar
• Tiraboschi E, Martina S, van der Ent W, et al. New insights into the early mechanisms of epileptogenesis in a zebrafish model of Dravet syndrome. Epilepsia. 2020 Mar;61:549–560.
   PubMed Web of Science ®Google Scholar
• Meador KJ. Seizure Reduction with Fluoxetine in Dravet Syndrome. Epilepsy Behav Case Rep. 2014 Jan 1;2:54–56.
   PubMedGoogle Scholar
• Vavers E, Zvejniece L, Maurice T, et al. Allosteric modulators of sigma-1 receptor: a review. Front Pharmacol. 2019;10:223.
   PubMed Web of Science ®Google Scholar
• Matsumoto RR, McCracken KA, Pouw B, et al. Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology. 2002 Jun;42:1043–1055.
   PubMed Web of Science ®Google Scholar
• Rousseaux CG, Greene SF. Sigma receptors [sigmaRs]: biology in normal and diseased states. J Recept Signal Transduct Res. 2016 Aug;36:327–388.
   PubMed Web of Science ®Google Scholar
• Guo L, Chen Y, Zhao R, et al. Allosteric modulation of sigma-1 receptors elicits anti-seizure activities. Br J Pharmacol. 2015 Aug;172:4052–4065.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Munoz M, Sanchez-Blazquez P, Garzon J. Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors. Oncotarget. 2018 May 4;9:23373–23389.
   PubMedGoogle Scholar
• Martin P, de Witte PAM, Maurice T, et al. Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav. 2020 Apr;105:106989.
   PubMed Web of Science ®Google Scholar
• Boyd B, Smith S, Gammaitoni A, et al. A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects. Int J Clin Pharmacol Ther. 2019 Jan;57:11–19.
   PubMed Web of Science ®Google Scholar
• Schoonjans AS, Lagae L, Ceulemans B. Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Ther Adv Neurol Disord. 2015 Nov;8:328–338.
   PubMed Web of Science ®Google Scholar
• Claes L, Del-Favero J, Ceulemans B, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001 Jun;68:1327–1332.
   PubMed Web of Science ®Google Scholar
• Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011 Apr;52:3–9.
   PubMedGoogle Scholar
• Ceulemans B, Schoonjans AS, Marchau F, et al. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016 Jul;57:e129–34.
   PubMed Web of Science ®Google Scholar
• Specchio N, Pietrafusa N, Ferretti A, et al. Successful use of fenfluramine in nonconvulsive status epilepticus of Dravet syndrome. Epilepsia. 2020 Apr;61:831–833.
   PubMed Web of Science ®Google Scholar
• Lai WW, Galer BS, Wong PC, et al. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study. Epilepsia. 2020 Aug 18;61:2386–2395.
   PubMed Web of Science ®Google Scholar
• Sullivan J, Scheffer IE, Lagae L, et al. Fenfluramine HCl (Fintepla®) provides long-term clinically meaningful reduction in seizure frequency: analysis of an ongoing open-label extension study. Epilepsia. 2020 Oct 19;61:2396–2404.
   PubMed Web of Science ®Google Scholar
• Schoonjans AS, Marchau F, Paelinck BP, et al. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. Curr Med Res Opin. 2017 Oct;33:1773–1781.
   PubMed Web of Science ®Google Scholar
• Specchio N, Pietrafusa N, Doccini V, et al. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a real-world study. Epilepsia. 2020 Sep 18;61:2405–2414.
   Web of Science ®Google Scholar
• Zhang H, Zhao H, Yang X, et al. 5-Hydroxytryptophan, a precursor for serotonin synthesis, reduces seizure-induced respiratory arrest. Epilepsia. 2016 Aug;57:1228–1235.
   PubMed Web of Science ®Google Scholar
• Tupal S, Faingold CL. Fenfluramine, a serotonin-releasing drug, prevents seizure-induced respiratory arrest and is anticonvulsant in the DBA/1 mouse model of SUDEP. Epilepsia. 2019 Mar;60:485–494.
   PubMed Web of Science ®Google Scholar
• Hatini PG, Commons KG. A 5-HT1D -receptor agonist protects Dravet syndrome mice from seizure and early death. Eur J Neurosci. 2020 May 11;52:4370–4374.
   PubMed Web of Science ®Google Scholar
• Dutton SBB, Dutt K, Papale LA, et al. Early-life febrile seizures worsen adult phenotypes in Scn1a mutants. Exp Neurol. 2017 Jul;293:159–171.
   PubMed Web of Science ®Google Scholar
• Nabbout R, Auvin S, Chiron C, et al. Development and content validation of a preliminary core set of patient- and caregiver-relevant outcomes for inclusion in a potential composite endpoint for Dravet Syndrome. Epilepsy Behav. 2018 Jan;78:232–242.
   PubMed Web of Science ®Google Scholar